Stock Scorer
Stock Board CompareNew Screen Insiders ETFNew
Donate
…
Report Measures Companies Earnings calendar Insider buying Fund portfolios Congress trades ETFs
Sign in

Iovance Biotherapeutics, Inc. (IOVA) · Insider trading

What Iovance Biotherapeutics's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$0
0 insiders
Net, 12 months
$0
bought less sold
Latest filing
2026-09-10
filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

2024-11: $503,000 sold 2025-01 2025-05: $51,994 bought 2025-06: $55,200 bought 2025-07 2026-01 2026-07
Bought Sold Largest month: $503,000

Who traded, two years

InsiderBoughtSold TradesLast tradeHolds after
Maynard Ryan DDirector – $503,000 1 2024-11-12 7,500
Kirby Daniel GordonChief Commercial Officer $55,200 – 1 2025-06-05 30,000
Vogt Frederick GDirector, Interim CEO & General Counsel $42,250 – 1 2025-05-14 374,646
Puri Raj K.Chief Regulatory Officer $9,744 – 1 2025-05-23 206,852

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

DateInsiderTradeShares PriceValueHolds afterFiling
2025-06-05 Kirby Daniel GordonChief Commercial Officer Buy 30,000 1.84 $55,200 30,000 Form 4
2025-05-23 Puri Raj K.Chief Regulatory Officer Buy 5,600 1.74 $9,744 206,852 Form 4
2025-05-14 Vogt Frederick GDirector, Interim CEO & General Counsel Buy 25,000 1.69 $42,250 374,646 Form 4
2024-11-12 Maynard Ryan DDirector Sale 50,000 10.06 $503,000 7,500 Form 4

Grants, exercises and other transactions

Pay, tax and paperwork rather than a choice to trade at the market price. Two years.

57 × option exercise56 × shares withheld for tax
Show them
DateInsiderWhatShares PriceHolds afterFiling
2026-09-08 Puri Raj K.Chief Regulatory Officer Option exercise M +9,766 – 260,842 Form 4
2026-09-08 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −4,478 8.70 256,364 Form 4
2026-09-08 Bilinsky IgorChief Operating Officer Option exercise M +7,813 – 146,050 Form 4
2026-09-08 Bilinsky IgorChief Operating Officer Shares withheld for tax F −3,976 8.70 142,074 Form 4
2026-09-08 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +15,626 – 602,085 Form 4
2026-09-08 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −6,638 8.70 595,447 Form 4
2026-09-01 Bilinsky IgorChief Operating Officer Option exercise M +8,789 – 142,709 Form 4
2026-09-01 Bilinsky IgorChief Operating Officer Shares withheld for tax F −4,472 8.28 138,237 Form 4
2026-09-01 Puri Raj K.Chief Regulatory Officer Option exercise M +5,470 – 253,584 Form 4
2026-09-01 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −2,508 8.28 251,076 Form 4
2026-09-01 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +41,669 – 604,161 Form 4
2026-09-01 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −17,702 8.28 586,459 Form 4
2026-08-10 Kirby Daniel GordonChief Commercial Officer Option exercise M +10,001 – 156,947 Form 4
2026-08-10 Kirby Daniel GordonChief Commercial Officer Shares withheld for tax F −2,436 6.40 154,511 Form 4
2026-08-06 Roche Corleen M.Chief Financial Officer Option exercise M +49,995 – 49,995 Form 4
2026-08-06 Roche Corleen M.Chief Financial Officer Shares withheld for tax F −21,238 6.21 28,757 Form 4
2026-06-05 Bilinsky IgorChief Operating Officer Option exercise M +7,813 – 137,896 Form 4
2026-06-05 Bilinsky IgorChief Operating Officer Shares withheld for tax F −3,976 4.23 133,920 Form 4
2026-06-05 Puri Raj K.Chief Regulatory Officer Option exercise M +9,766 – 251,957 Form 4
2026-06-05 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −3,843 4.23 248,114 Form 4
2026-06-05 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +7,813 – 144,087 Form 4
2026-06-05 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −3,976 4.23 140,111 Form 4
2026-06-05 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +15,625 – 569,130 Form 4
2026-06-05 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −6,638 4.23 562,492 Form 4
2026-06-01 Bilinsky IgorChief Operating Officer Option exercise M +8,790 – 134,556 Form 4
2026-06-01 Bilinsky IgorChief Operating Officer Shares withheld for tax F −4,473 3.96 130,083 Form 4
2026-06-01 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +8,790 – 140,747 Form 4
2026-06-01 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −4,473 3.96 136,274 Form 4
2026-06-01 Puri Raj K.Chief Regulatory Officer Option exercise M +5,469 – 244,699 Form 4
2026-06-01 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −2,508 3.96 242,191 Form 4
2026-06-01 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +41,668 – 571,206 Form 4
2026-06-01 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −17,701 3.96 553,505 Form 4
2026-05-11 Kirby Daniel GordonChief Commercial Officer Option exercise M +10,000 – 149,381 Form 4
2026-05-11 Kirby Daniel GordonChief Commercial Officer Shares withheld for tax F −2,435 3.70 146,946 Form 4
2026-03-05 Bilinsky IgorChief Operating Officer Option exercise M +31,246 – 142,394 Form 4
2026-03-05 Bilinsky IgorChief Operating Officer Shares withheld for tax F −16,628 4.58 125,766 Form 4
2026-03-05 Puri Raj K.Chief Regulatory Officer Option exercise M +39,059 – 257,590 Form 4
2026-03-05 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −18,360 4.58 239,230 Form 4
2026-03-05 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +31,246 – 148,477 Form 4
2026-03-05 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −16,520 4.58 131,957 Form 4
2026-03-05 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +62,493 – 556,293 Form 4
2026-03-05 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −26,755 4.58 529,538 Form 4
2026-03-02 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +12,697 – 124,353 Form 4
2026-03-02 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −7,122 3.79 117,231 Form 4
2026-03-02 Puri Raj K.Chief Regulatory Officer Option exercise M +5,470 – 221,329 Form 4
2026-03-02 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −2,798 3.79 218,531 Form 4
2026-03-02 Bilinsky IgorChief Operating Officer Option exercise M +12,307 – 118,051 Form 4
2026-03-02 Bilinsky IgorChief Operating Officer Shares withheld for tax F −6,903 3.79 111,148 Form 4
2026-03-02 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +52,087 – 516,609 Form 4
2026-03-02 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −22,809 3.79 493,800 Form 4
2026-02-24 Kirby Daniel GordonChief Commercial Officer Option exercise M +120,000 – 173,546 Form 4
2026-02-24 Kirby Daniel GordonChief Commercial Officer Shares withheld for tax F −34,165 3.78 139,381 Form 4
2026-02-10 Kirby Daniel GordonChief Commercial Officer Option exercise M +39,996 – 69,996 Form 4
2026-02-10 Kirby Daniel GordonChief Commercial Officer Shares withheld for tax F −16,450 2.60 53,546 Form 4
2025-12-02 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +10,417 – 468,948 Form 4
2025-12-02 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −4,426 2.14 464,522 Form 4
2025-12-02 Bilinsky IgorChief Operating Officer Option exercise M +3,516 – 107,530 Form 4
2025-12-02 Bilinsky IgorChief Operating Officer Shares withheld for tax F −1,786 2.14 105,744 Form 4
2025-12-02 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +3,906 – 113,640 Form 4
2025-12-02 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −1,984 2.14 111,656 Form 4
2025-12-01 Puri Raj K.Chief Regulatory Officer Option exercise M +5,469 – 218,326 Form 4
2025-12-01 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −2,467 2.23 215,859 Form 4
2025-12-01 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +41,669 – 476,232 Form 4
2025-12-01 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −17,701 2.23 458,531 Form 4
2025-12-01 Bilinsky IgorChief Operating Officer Option exercise M +8,789 – 108,478 Form 4
2025-12-01 Bilinsky IgorChief Operating Officer Shares withheld for tax F −4,464 2.23 104,014 Form 4
2025-12-01 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +8,789 – 114,198 Form 4
2025-12-01 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −4,464 2.23 109,734 Form 4
2025-09-02 Bilinsky IgorChief Operating Officer Option exercise M +12,306 – 105,939 Form 4
2025-09-02 Bilinsky IgorChief Operating Officer Shares withheld for tax F −6,250 2.19 99,689 Form 4
2025-09-02 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +12,697 – 111,857 Form 4
2025-09-02 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −6,448 2.19 105,409 Form 4
2025-09-02 Puri Raj K.Chief Regulatory Officer Option exercise M +5,470 – 215,324 Form 4
2025-09-02 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −2,467 2.19 212,857 Form 4
2025-09-02 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +52,086 – 456,690 Form 4
2025-09-02 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −22,127 2.19 434,563 Form 4
2025-06-02 Bellemin Jean-MarcChief Financial Officer Option exercise M +8,789 – 64,993 Form 4
2025-06-02 Bellemin Jean-MarcChief Financial Officer Shares withheld for tax F −4,464 1.76 60,529 Form 4
2025-06-02 Bilinsky IgorChief Operating Officer Option exercise M +12,305 – 99,883 Form 4
2025-06-02 Bilinsky IgorChief Operating Officer Shares withheld for tax F −6,250 1.76 93,633 Form 4
2025-06-02 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +12,695 – 105,608 Form 4
2025-06-02 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −6,448 1.76 99,160 Form 4
2025-06-02 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +52,085 – 426,731 Form 4
2025-06-02 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −22,127 1.76 404,604 Form 4
2025-06-02 Puri Raj K.Chief Regulatory Officer Option exercise M +5,469 – 212,321 Form 4
2025-06-02 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −2,467 1.76 209,854 Form 4
2025-03-14 Puri Raj K.Chief Regulatory Officer Option exercise M +8,334 – 203,761 Form 4
2025-03-14 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −2,509 3.59 201,252 Form 4
2025-03-03 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +62,497 – 126,383 Form 4
2025-03-03 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −33,470 4.04 92,913 Form 4
2025-03-03 Puri Raj K.Chief Regulatory Officer Option exercise M +59,999 – 215,411 Form 4
2025-03-03 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −19,984 4.04 195,427 Form 4
2025-03-03 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +223,943 – 445,059 Form 4
2025-03-03 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −95,413 4.04 349,646 Form 4
2025-03-03 Bilinsky IgorChief Operating Officer Option exercise M +62,106 – 120,880 Form 4
2025-03-03 Bilinsky IgorChief Operating Officer Shares withheld for tax F −33,302 4.04 87,578 Form 4
2025-03-03 Bellemin Jean-MarcChief Financial Officer Option exercise M +58,590 – 87,938 Form 4
2025-03-03 Bellemin Jean-MarcChief Financial Officer Shares withheld for tax F −31,734 4.04 56,204 Form 4
2025-01-14 Bilinsky IgorChief Operating Officer Option exercise M +2,813 – 60,352 Form 4
2025-01-14 Bilinsky IgorChief Operating Officer Shares withheld for tax F −1,578 5.89 58,774 Form 4
2025-01-14 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +2,813 – 65,464 Form 4
2025-01-14 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −1,578 5.89 63,886 Form 4
2025-01-14 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +20,835 – 231,071 Form 4
2025-01-14 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −9,955 5.89 221,116 Form 4
2024-12-16 Puri Raj K.Chief Regulatory Officer Option exercise M +8,334 – 159,171 Form 4
2024-12-16 Puri Raj K.Chief Regulatory Officer Shares withheld for tax F −3,759 7.84 155,412 Form 4
2024-12-02 Graf Finckenstein FriedrichChief Medical Officer Option exercise M +3,906 – 64,633 Form 4
2024-12-02 Graf Finckenstein FriedrichChief Medical Officer Shares withheld for tax F −1,982 9.07 62,651 Form 4
2024-12-02 Bilinsky IgorChief Operating Officer Option exercise M +3,516 – 59,323 Form 4
2024-12-02 Bilinsky IgorChief Operating Officer Shares withheld for tax F −1,784 9.07 57,539 Form 4
2024-12-02 Vogt Frederick GDirector, Interim CEO & General Counsel Option exercise M +10,417 – 214,662 Form 4
2024-12-02 Vogt Frederick GDirector, Interim CEO & General Counsel Shares withheld for tax F −4,426 9.07 210,236 Form 4
2024-11-12 Maynard Ryan DDirector Option exercise M +50,000 7.45 57,500 Form 4

How to read it

Buy, sale
Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan
A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after
The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value
Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

Iovance Biotherapeutics's scores and multiples ›